Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Volume Increase – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw strong trading volume on Thursday . 2,055 shares traded hands during trading, a decline of 34% from the previous session’s volume of 3,096 shares.The stock last traded at $45.0150 and had previously closed at $45.50.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, Berenberg Bank lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Two research analysts have rated the stock with a Strong Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, Zealand Pharma A/S currently has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Performance

The stock’s 50 day moving average price is $46.01 and its 200 day moving average price is $51.52. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The company has a market cap of $3.22 billion, a price-to-earnings ratio of 3.34 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The firm had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. On average, analysts expect that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.